<p>德国曼海姆，2025 年 5 月 14 日（GLOBE NEWSWIRE）——Affimed N.V.是一家临床阶段的免疫肿瘤学公司，致力于让患者恢复与生俱来的抗癌能力，今天宣布已收到纳斯达克上市资格部门（“工作人员”）的书面通知，通知公司根据纳斯达克上市规则 5101、5110(b) 和 IM-5101-1，自 2025 年 5 月 20 日开盘起，公司普通股的交易将被暂停，并将向美国证券交易委员会提交 25 号表格以将公司的证券从纳斯达克证券市场（“纳斯达克”）退市。</p>
<p>工作人员的决定基于以下原因：（i）公司宣布在德国曼海姆当地法院申请破产所引发的公众利益相关问题，（ii）对现有上市证券持有者的剩余股权利益的担忧，以及（iii）对公司维持符合纳斯达克持续上市所有要求的能力的担忧。公司不打算对这一决定提出上诉。</p>
<p>如之前所述，2025 年 5 月 13 日，公司已向德国曼海姆当地法院申请破产。</p>
<p><strong>关于 Affimed N.V.</strong></p>
<p>Affimed 是一家临床阶段的免疫肿瘤学公司，致力于通过实现先天免疫系统未被开发的潜力，让患者恢复与生俱来的抗癌能力。公司的先天细胞连接剂（ICE®）使肿瘤靶向识别和杀死多种血液和实体肿瘤成为可能。ICE®是在公司专有的 ROCK®平台上生成的，该平台可预测性地生成定制分子，利用先天免疫细胞的力量摧毁肿瘤细胞。多种 ICE®分子正在临床开发中，作为单药或联合疗法进行研究。Affimed 总部位于德国曼海姆，由一支经验丰富的生物技术和制药领导团队领导，他们团结在一个大胆的愿景下，旨在阻止癌症干扰患者的生活。有关公司人员、产品管线和合作伙伴的更多信息，请访问：www.affimed.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含前瞻性声明。除历史事实陈述外，所有声明均为前瞻性声明，通常以 “预期”、“相信”、“可能”、“估计”、“期望”、“目标”、“打算”、“期待”、“可能”、“计划”、“潜在”、“预测”、“项目”、“应该”、“将”、“会” 和类似表达方式来表示。前瞻性声明包括但不限于关于公司普通股上市和交易的声明。由于某些风险、不确定性和其他因素，实际结果可能与公司前瞻性声明所预期的结果有重大差异，这些因素在公司向证券交易委员会提交的文件中 “风险因素” 一节中有描述。鉴于这些风险、不确定性和其他因素，您不应对这些前瞻性声明过于依赖，公司也不承担更新这些前瞻性声明的义务，即使未来有新信息可用。</p>
<p><strong>投资者关系联系人</strong></p>
<p>亚历山大·富杜基迪斯</p>
<p>投资者关系总监</p>
<p>电子邮件：a.fudukidis@affimed.com</p>
<p>电话：+1 (917) 436-8102</p>
<p><strong>媒体联系人</strong></p>
<p>玛丽·贝丝·桑丁</p>
<p>市场与传播副总裁</p>
<p>电子邮件：m.sandin@affimed.com</p>

AFMD

AFMDQ

<p>Affimed N.V. 因在德国曼海姆申请破产而收到纳斯达克的退市通知，原因是公众利益的担忧。该公司的普通股将于 2025 年 5 月 20 日暂停交易，并将向美国证券交易委员会提交退市通知表格 25。Affimed 不打算对这一决定提出上诉，该决定反映了对公司是否符合纳斯达克上市要求以及现有证券持有者利益的担忧</p>

<p>MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) — Affimed N.V. , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company’s common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist the Company’s securities from The Nasdaq Stock Market (“Nasdaq”).</p>
<div class="lb-trans"><p>德国曼海姆，2025 年 5 月 14 日（GLOBE NEWSWIRE）——Affimed N.V.是一家临床阶段的免疫肿瘤学公司，致力于让患者恢复与生俱来的抗癌能力，今天宣布已收到纳斯达克上市资格部门（“工作人员”）的书面通知，通知公司根据纳斯达克上市规则 5101、5110(b) 和 IM-5101-1，自 2025 年 5 月 20 日开盘起，公司普通股的交易将被暂停，并将向美国证券交易委员会提交 25 号表格以将公司的证券从纳斯达克证券市场（“纳斯达克”）退市。</p>
</div><p>The Staff’s determination was based on (i) the associated public interest concerns raised by the Company’s announcement that it filed for insolvency in the local court of Mannheim in Germany, (ii) concerns regarding the residual equity interest of the existing listed securities holders and (iii) concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq. The Company does not expect to appeal this determination.</p>
<div class="lb-trans"><p>工作人员的决定基于以下原因：（i）公司宣布在德国曼海姆当地法院申请破产所引发的公众利益相关问题，（ii）对现有上市证券持有者的剩余股权利益的担忧，以及（iii）对公司维持符合纳斯达克持续上市所有要求的能力的担忧。公司不打算对这一决定提出上诉。</p>
</div><p>As previously reported, on May 13, 2025, the Company filed for insolvency with the local court of Mannheim in Germany.</p>
<div class="lb-trans"><p>如之前所述，2025 年 5 月 13 日，公司已向德国曼海姆当地法院申请破产。</p>
</div><p><strong>About Affimed N.V.</strong></p>
<div class="lb-trans"><p><strong>关于 Affimed N.V.</strong></p>
</div><p>Affimed  is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.</p>
<div class="lb-trans"><p>Affimed 是一家临床阶段的免疫肿瘤学公司，致力于通过实现先天免疫系统未被开发的潜力，让患者恢复与生俱来的抗癌能力。公司的先天细胞连接剂（ICE®）使肿瘤靶向识别和杀死多种血液和实体肿瘤成为可能。ICE®是在公司专有的 ROCK®平台上生成的，该平台可预测性地生成定制分子，利用先天免疫细胞的力量摧毁肿瘤细胞。多种 ICE®分子正在临床开发中，作为单药或联合疗法进行研究。Affimed 总部位于德国曼海姆，由一支经验丰富的生物技术和制药领导团队领导，他们团结在一个大胆的愿景下，旨在阻止癌症干扰患者的生活。有关公司人员、产品管线和合作伙伴的更多信息，请访问：www.affimed.com。</p>
</div><p><strong>FORWARD-LOOKING STATEMENTS</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements include, among other things, statements regarding the listing and trading of the Company’s common shares. Actual results may differ materially from the results anticipated by the Company’s forward-looking statements due to certain risks, uncertainties and other factors described under the heading “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.</p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明。除历史事实陈述外，所有声明均为前瞻性声明，通常以 “预期”、“相信”、“可能”、“估计”、“期望”、“目标”、“打算”、“期待”、“可能”、“计划”、“潜在”、“预测”、“项目”、“应该”、“将”、“会” 和类似表达方式来表示。前瞻性声明包括但不限于关于公司普通股上市和交易的声明。由于某些风险、不确定性和其他因素，实际结果可能与公司前瞻性声明所预期的结果有重大差异，这些因素在公司向证券交易委员会提交的文件中 “风险因素” 一节中有描述。鉴于这些风险、不确定性和其他因素，您不应对这些前瞻性声明过于依赖，公司也不承担更新这些前瞻性声明的义务，即使未来有新信息可用。</p>
</div><p><strong>Investor Relations Contact</strong></p>
<div class="lb-trans"><p><strong>投资者关系联系人</strong></p>
</div><p>Alexander Fudukidis</p>
<div class="lb-trans"><p>亚历山大·富杜基迪斯</p>
</div><p>Director, Investor Relations</p>
<div class="lb-trans"><p>投资者关系总监</p>
</div><p>E-Mail: a.fudukidis@affimed.com</p>
<div class="lb-trans"><p>电子邮件：a.fudukidis@affimed.com</p>
</div><p>Tel.: +1 (917) 436-8102</p>
<div class="lb-trans"><p>电话：+1 (917) 436-8102</p>
</div><p><strong>Media Contact</strong></p>
<div class="lb-trans"><p><strong>媒体联系人</strong></p>
</div><p>Mary Beth Sandin</p>
<div class="lb-trans"><p>玛丽·贝丝·桑丁</p>
</div><p>Vice President, Marketing and Communications</p>
<div class="lb-trans"><p>市场与传播副总裁</p>
</div><p>E-Mail: m.sandin@affimed.com</p>
<div class="lb-trans"><p>电子邮件：m.sandin@affimed.com</p>
</div>

Affimed 宣布收到纳斯达克退市警告